ReNewVax

ReNewVax Offering  

Convertible Redeemable Preference Shares

Recommendation

Reporting Currency

Use of funds

 

 

BUY

Pound Sterling

Growth
Sector Biotech – vaccines
Key Market Data  
Market Private Offering
Price per Share €1
Number of shares for sale 3,000,000
Total €3,000,000.00
Company Value €29,000,000
Interest
Term

15% Compounded

5 years
Fiscal Year end 31st December
Company Objective Growth

Main Shareholders

 

University of Liverpool 37%

Management Team 60%

ReNewVax – 15 % cumulative redeemable preference share offering.

 

ReNewVax’s stated aim is to prevent life-threatening bacterial infections and combat antimicrobial resistance with vaccines. ReNewVax is a next generation vaccine company developing therapeutic vaccines targeting some of the world’s most acute bacterial disease challenges.

Spun out of the University of Liverpool (UoL) to commercialise the intellectual property generatedfrom the work of Dr Marie Yang and Professor Aras Kadioglu, exploiting a reverse vaccinology strategy, ReNewVax is deploying genomic-led, rational discovery approaches to produce a pipeline of programs that offer protection beyond existing traditional vaccines, which opens up access and delivers a step-change in global health security.

OBTAIN OFFERING DETAILS
BACK